Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06345001 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
A Phase 1 study of Solid Tumors and Hepatocellular Carcinoma (HCC), sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 4
- Study locations
NCT06345001 is a Phase 1 study of Solid Tumors and Hepatocellular Carcinoma (HCC) that has completed, run by Bayer. The registered enrollment target is 14 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06345001, a Phase 1 study of Solid Tumors and Hepatocellular Carcinoma (HCC), has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 4
- Study locations
Study Summary
Researchers are studying a new potential treatment for liver cancer or other select solid cancers. To do this, researchers have developed a protein, called a monoclonal antibody, which can find and attach itself to another protein present on the surface of cancer cells. This can help the new treatment to specifically target cancer cells. In this study, researchers want to understand the distribution and processing of this monoclonal antibody in people with liver cancer or other select solid cancers. Researchers will use the following two forms of monoclonal antibody as study interventions during this study: * BAY3630942: This is the monoclonal antibody attached to a tracer. A tracer emits radiation that can help researchers track the monoclonal antibody in the body using imaging tests like PET/CT (positron emission tomography / computed tomography). All participants will receive a fixed dose of BAY3630942 during the study. * BAY3547922: This is the monoclonal antibody without the tracer. Participants may receive different amounts of BAY3547922 during the study. In this study, participants will not derive therapeutic benefit from receiving BAY3630942 or BAY3547922. However, this study may help researchers develop a new treatment for people with liver cancer or other select solid cancers and find a dose to be tested in future studies. The main purpose of this first-in-human study is to check how BAY3630942 distributes among different organs in the body and how much of the radiation it emits is absorbed by the organs based on the total dose of BAY3630942 and BAY3547922 given. For this, the researchers will: * measure the amount of BAY3630942 radiation found in different organs over time. * measure the amount of BAY3630942 radiation absorbed by different organs. * use the above information to estimate the amount of radiation that would be absorbed by the same organs from the new potential treatment. Researchers will also monitor the number and severity of medica
Conditions Studied
Interventions
- DRUG BAY3630942
- DRUG BAY3547922
Study Locations (4)
California
- City of Hope - Duarte Cancer Center - Duarte
- University of Southern California (USC) - Norris Comprehensive Cancer Center - Los Angeles
Arizona
- HonorHealth Research Institute - Scottsdale
Florida
- Biogenix Molecular, LLC - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2024-08-26 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06345001
The ClinicalTrials.gov registry entry for NCT06345001 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (95% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which BAY3630942 is the first listed.
NCT06345001 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06345001 about?
NCT06345001 is a clinical study titled "A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers". Researchers are studying a new potential treatment for liver cancer or other select solid cancers. To do this, researchers have developed a protein, called a monoclonal antibody, which can find and attach itself to another protein present on the surface of cancer cells. This can help the new treatm...
What is the current status of trial NCT06345001?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2024-08-26. Estimated completion is 2025-03-31.
What conditions does trial NCT06345001 study?
This clinical trial studies the following conditions: Solid Tumors, Hepatocellular Carcinoma (HCC).
What interventions are being tested in trial NCT06345001?
The interventions under investigation include: BAY3630942 (DRUG), BAY3547922 (DRUG).
Who is sponsoring clinical trial NCT06345001?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06345001 being conducted?
This trial has 4 study locations across Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.